Mammalian Glyco-Engineering

Our mammalian glyco-engineering research interest is the glycosylation modification of the therapeutic proteins (such tPA, EPO, Cholineesterase). We use different mammalian cell lines such as (CHO, BHK, HEK293) as protein production vehicles to produce the therapeutic proteins very similar to the native protein. Common treatment using such proteins required a huge dosage to reach the medical effect. However, such usage may trigger side effect such as immune response. To evade such situation, Our goal is to use glyco-enginnering approach to improve the efficacy of these therapeutics.

References

Bennun, Sandra V., Kevin J. Yarema, Michael J. Betenbaugh, and Frederick J. Krambeck. "Integration of the Transcriptome and Glycome for Identification of Glycan Cell Signatures." Computational Biology (10 January 2013, 2013).